Top

Targeted Oncology

Published in:

01-06-2019 | Lung Cancer | Original Research Article

Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases

Authors: Ruofan Huang, Xiao Xu, Dong Li, Kun Chen, Qiong Zhan, Mengxi Ge, Xinli Zhou, Xiaohua Liang, Ming Guan

Published in: Targeted Oncology | Issue 3/2019

Abstract

Background

The presence of specific mutations in the EGFR gene informs the clinical pathway of therapy for patients with lung adenocarcinoma (LAC), including those with central nervous system (CNS) metastases. Plasma circulating cell-free DNA (cfDNA) has been demonstrated to carry the mutational information of LACs, which serves as a biomarker to guide treatment. However, whether the cerebrospinal fluid (CSF) enriches circulating tumor DNA (ctDNA) released from CNS metastatic lesions of LAC, and whether the CSF ctDNA can be used to characterize these lesions remains unknown.

Objective

To explore the EGFR status in CNS metastases of LAC patients, and to guide the treatment of intra- and extracranial tumors in these patients.

Patients and methods

The EGFR mutational status in the cfDNA from paired CSF and plasma samples from LAC patients with CNS metastases, including 20 brain metastases (BM) and 15 leptomeningeal metastases (LM), was assessed by droplet digital polymerase chain reaction (ddPCR). The clinical outcomes of the EGFR status-based intervention were investigated.

Results

EGFR mutations were detected in 23/35 LAC patients (65.7%). EGFR mutations in the plasma or CSF were detected in 6/11 (54.5%) and 5/10 (50%) BM patients, and in 4/11 (36.4%) and 9/12(75%) LM patients, respectively. The prevalence of the T790M mutation was significantly higher in plasma (9/23) than in CSF (3/23) samples. The sensitivity and specificity of the ddPCR-based EGFR mutation test in CSF or plasma samples versus the primary tumor samples were 56% and 89% versus 46% and 100%, respectively. Twelve patients received a first-generation EGFR TKI (tyrosine kinase inhibitor) after the detection of sensitive EGFR mutations in their CSF or plasma, and five patients were switched from a first-generation EGFR TKI to osimertinib after the detection of the T790M mutation.

Conclusions

The EGFR T790M mutation in plasma cfDNA is a sensitive marker for EGFR TKI resistance when CNS metastases progressed. CSF ctDNA increases the diagnostic validity for EGFR genotyping of lung cancer brain metastasis. ddPCR in CSF and plasma samples could provide less invasive and close monitoring of the EGFR status of LAC patients with CNS metastases.

Available only for authorised users

Kromer C, Xu J, Ostrom QT, Gittleman H, Kruchko C, Sawaya R, et al. Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study. J Neurooncol. 2017;134(1):55–64. https://doi.org/10.1007/s11060-017-2516-7.CrossRefPubMed

Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018;19(1):e43–55. https://doi.org/10.1016/S1470-2045(17)30689-7.CrossRefPubMed

Ge M, Zhuang Y, Zhou X, Huang R, Liang X, Zhan Q. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases. J Neurooncol. 2017;135(2):413–8. https://doi.org/10.1007/s11060-017-2590-x.CrossRefPubMed

Rau KM, Chen HK, Shiu LY, Chao TL, Lo YP, Wang CC, et al. Discordance of mutation statuses of epidermal growth factor receptor and K-ras between primary adenocarcinoma of lung and brain metastasis. Int J Mol Sci. 2016;17(4):524. https://doi.org/10.3390/ijms17040524.CrossRefPubMedPubMedCentral

Lee CK, Lord S, Marschner I, Wu YL, Sequist L, Rosell R, et al. The value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer. J Thorac Oncol. 2018;13(6):792–800. https://doi.org/10.1016/j.jtho.2018.03.010.CrossRefPubMed

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18(16):4406–14.CrossRefPubMedPubMedCentral

Hasegawa T, Sawa T, Futamura Y, Horiba A, Ishiguro T, Marui T, et al. Feasibility of rebiopsy in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors. Intern Med. 2015;54(16):1977–80. https://doi.org/10.2169/internalmedicine.54.4394.CrossRefPubMed

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. https://doi.org/10.1126/scitranslmed.3007094.CrossRefPubMedPubMedCentral

Wang Y, Liu Z, Yin H, Hu J, Zhong S, Chen W, et al. Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient. Gene. 2018;644:87–92. https://doi.org/10.1016/j.gene.2017.10.073.CrossRefPubMed

10.

Connolly ID, Li Y, Pan W, Johnson E, You L, Vogel H, et al. A pilot study on the use of cerebrospinal fluid cell-free DNA in intramedullary spinal ependymoma. J Neurooncol. 2017;135(1):29–36. https://doi.org/10.1007/s11060-017-2557-y.CrossRefPubMedPubMedCentral

11.

Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, et al. Evaluating circulating tumor DNA from the cerebrospinal fluid of patients with melanoma and leptomeningeal disease. J Neuropathol Exp Neurol. 2018;77(7):628–35. https://doi.org/10.1093/jnen/nly046.CrossRefPubMedPubMedCentral

12.

Pinheiro LB, Coleman VA, Hindson CM, Herrmann J, Hindson BJ, Bhat S, et al. Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification. Anal Chem. 2012;84(2):1003–11. https://doi.org/10.1021/ac202578x.CrossRefPubMed

13.

Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, et al. Primary resistance to osimertinib due to SCLC transformation: issue of T790M determination on liquid re-biopsy. Lung Cancer. 2018;115:21–7. https://doi.org/10.1016/j.lungcan.2017.11.011.CrossRefPubMed

14.

Martinez-Ricarte F, Mayor R, Martinez-Saez E, Rubio-Perez C, Pineda E, Cordero E, et al. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid. Clin Cancer Res. 2018;24(12):2812–9. https://doi.org/10.1158/1078-0432.CCR-17-3800.CrossRefPubMed

15.

Liang S, Zhe L, Jungfang T, Hongbo W, Lili G, Mingzhi L, et al. EGFR mutation status analysis in cerebrospinal fluid and plasma of advanced lung adenocarcinoma with brain metastases. J Thorac Oncol. 2017;12(1):S240.CrossRef

16.

Joo JW, Hong MH, Shim HS. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. Lung Cancer. 2018;121:12–7. https://doi.org/10.1016/j.lungcan.2018.04.013.CrossRefPubMed

17.

Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Masago K, et al. Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases. Anticancer Res. 2015;35(2):1025–31.PubMed

18.

Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations. Cancer. 2013;119(24):4325–32. https://doi.org/10.1002/cncr.28364.CrossRefPubMed

19.

Jiang BY, Li YS, Guo WB, Zhang XC, Chen ZH, Su J, et al. Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells. Clin Cancer Res. 2017;23(18):5480–8. https://doi.org/10.1158/1078-0432.CCR-17-0047.CrossRefPubMed

20.

Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol. 2018;14(11):1117–32. https://doi.org/10.2217/fon-2017-0636.CrossRefPubMed

21.

Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70(3):399–405. https://doi.org/10.1007/s00280-012-1929-4.CrossRefPubMed

22.

Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, et al. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci. 2013;104(9):1198–204. https://doi.org/10.1111/cas.12211.CrossRefPubMedPubMedCentral

23.

Watanabe M, Kawaguchi T, Isa S, Ando M, Tamiya A, Kubo A, et al. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin Cancer Res. 2015;21(15):3552–60. https://doi.org/10.1158/1078-0432.CCR-14-2151.CrossRefPubMed

24.

Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 2008;99(5):929–35. https://doi.org/10.1111/j.1349-7006.2008.00782.x.CrossRefPubMed

25.

Cabanero M, Tsao MS. Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer. Curr Oncol. 2018;25(Suppl 1):S38–44. https://doi.org/10.3747/co.25.3761.CrossRefPubMedPubMedCentral

26.

Ge M, Zhan Q, Zhang Z, Ji X, Zhou X, Huang R, et al. Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases. BMC Cancer. 2019;19(1):143. https://doi.org/10.1186/s12885-019-5348-3.CrossRefPubMedPubMedCentral

Title: Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases
Authors: Ruofan Huang
Xiao Xu
Dong Li
Kun Chen
Qiong Zhan
Mengxi Ge
Xinli Zhou
Xiaohua Liang
Ming Guan
Publication date: 01-06-2019
Publisher: Springer International Publishing
Keywords: Lung Cancer
Metastasis
Lung Cancer
Tyrosine Kinase Inhibitors
CNS Metastasis
Lung Cancer
Tyrosine Kinase Inhibitors
Osimertinib
Published in: Targeted Oncology / Issue 3/2019
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-019-00645-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Authors’ Reply to Yu: “Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry”

Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice

MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer

Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China

Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies

The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes

Keynote webinar | Spotlight on antibody–drug conjugates in cancer